Scroll

levomilnacipran 🐶 Veterinary Use | Indications/Contra | FAERs-F | FAERs-M | Orange Bk | BioActivity |

Stem definition	Drug id	CAS RN
	4864	96847-54-0

Description:

Molecule	Description
Molfile Inchi Smiles Synonyms: levomilnacipran levomilnacipran hydrochloride fetzima levomilnacipran HCl	a selective serotonin and norepinephrine reuptake inhibitor (SNRI), mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system Molecular weight: 246.35 Formula: C15H22N2O CLOGP: 1.91 LIPINSKI: 0 HAC: 3 HDO: 1 TPSA: 46.33 ALOGS: -2.30 ROTB: 5 Status: OFP Legend: OFP - off patent OFM - off market ONP - on patent

Molecule

Description

Molfile Inchi Smiles

Synonyms:

levomilnacipran
levomilnacipran hydrochloride
fetzima
levomilnacipran HCl

a selective serotonin and norepinephrine reuptake inhibitor (SNRI), mechanism of the antidepressant action of levomilnacipran is unknown, but is thought to be related to the potentiation of serotonin and norepinephrine in the central nervous system

Molecular weight: 246.35
Formula: C15H22N2O
CLOGP: 1.91
LIPINSKI: 0
HAC: 3
HDO: 1
TPSA: 46.33
ALOGS: -2.30
ROTB: 5

Status: OFP

Legend:
OFP - off patent
OFM - off market
ONP - on patent

Drug dosage:

Dose	Unit	Route
40	mg	O

ADMET properties:

Show entries

Search:

Property	Value	Reference
BA (Bioavailability)	0.88 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K
fu (Fraction unbound in plasma)	0.68 %	Kawashima H, Watanabe R, Esaki T, Kuroda M, Nagao C, Natsume-Kitatani Y, Ohashi R, Komura H, Mizuguchi K

Showing 1 to 2 of 2 entries

Previous1Next

Approvals:

Date	Agency	Company	Orphan
July 25, 2013	FDA	FOREST LABS INC

FDA Adverse Event Reporting System (Female)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blepharospasm	333.13	36.97	68	1946	5928	63481080
Taste disorder	277.36	36.97	68	1946	13594	63473414
Epilepsy	235.70	36.97	69	1945	26996	63460012
Memory impairment	173.24	36.97	78	1936	104180	63382828
Migraine	154.90	36.97	72	1942	103274	63383734
Gastrooesophageal reflux disease	153.87	36.97	70	1944	95569	63391439
Paraesthesia	131.89	36.97	74	1940	156892	63330116
Hypoaesthesia	124.38	36.97	73	1941	168320	63318688
Abdominal pain upper	113.13	36.97	74	1940	206370	63280638
Persistent genital arousal disorder	96.22	36.97	15	1999	271	63486737

Showing 1 to 10 of 16 entries

Previous1 2Next

FDA Adverse Event Reporting System (Male)

None

FDA Adverse Event Reporting System (Geriatric)

Show entries

Search:

MedDRA adverse event term	Likelihood ratio	Likelihood ratio threshold	Patients taking drug having adverse event	Patients taking drug not having adverse event	Patients not taking drug having adverse event	Patients not taking drug not having adverse event
Blepharospasm	243.66	40.01	48	1482	5803	79737055
Taste disorder	196.09	40.01	48	1482	15775	79727083
Epilepsy	151.02	40.01	48	1482	40812	79702046
Memory impairment	133.13	40.01	57	1473	111677	79631181
Migraine	122.15	40.01	50	1480	87443	79655415
Gastrooesophageal reflux disease	113.70	40.01	50	1480	104196	79638662
Paraesthesia	99.82	40.01	54	1476	176269	79566589
Hypoaesthesia	98.96	40.01	54	1476	179298	79563560
Persistent genital arousal disorder	96.14	40.01	14	1516	267	79742591
Abdominal pain upper	85.27	40.01	53	1477	223766	79519092

Showing 1 to 10 of 12 entries

Previous1 2Next

FDA Adverse Event Reporting System (Pediatric)

None

Pharmacologic Action:

Show entries

Search:

Source	Code	Description
ATC	N06AX28	NERVOUS SYSTEM PSYCHOANALEPTICS ANTIDEPRESSANTS Other antidepressants
FDA EPC	N0000175749	Serotonin and Norepinephrine Reuptake Inhibitor
FDA MoA	N0000000102	Norepinephrine Uptake Inhibitors
FDA MoA	N0000000109	Serotonin Uptake Inhibitors
MeSH PA	D000928	Antidepressive Agents
MeSH PA	D002491	Central Nervous System Agents
MeSH PA	D049990	Membrane Transport Modulators
MeSH PA	D018377	Neurotransmitter Agents
MeSH PA	D014179	Neurotransmitter Uptake Inhibitors
MeSH PA	D011619	Psychotropic Drugs

Showing 1 to 10 of 11 entries

Previous1 2Next

Drug Use | Suggest Off label Use Form| |View source of the data|

Show entries

Search:

Disease	Relation	SNOMED_ID	DOID
Major depressive disorder	indication	370143000
Angle-closure glaucoma	contraindication	392291006	DOID:13550

Showing 1 to 2 of 2 entries

Previous1Next

🐶 Veterinary Drug Use

None

🐶 Veterinary products

None

Acid dissociation constants calculated using MoKa v3.0.0

Dissociation level	Dissociation constant	Type (acidic/basic)
pKa1	10.64	Basic

Orange Book patent data (new drug applications)

Show entries

Search:

Formulation strength	Trade name	Applicant	Application number	Approval date	Type	Dose form	Route	Patent number	Patent expiration date	Patent use
EQ 120MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	RE43879	Jan. 11, 2026	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 120MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	8481598	March 2, 2031	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 20MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	RE43879	Jan. 11, 2026	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 20MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	8481598	March 2, 2031	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 40MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	RE43879	Jan. 11, 2026	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 40MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	8481598	March 2, 2031	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 80MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	RE43879	Jan. 11, 2026	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)
EQ 80MG BASE	FETZIMA	ABBVIE	N204168	July 25, 2013	RX	CAPSULE, EXTENDED RELEASE	ORAL	8481598	March 2, 2031	TREATMENT OF MAJOR DEPRESSIVE DISORDER (MDD)

Showing 1 to 8 of 8 entries

Previous1Next

Orange Book exclusivity data (new drug applications)

None

Bioactivity Summary:

Show entries

Search:

Target	Class	Pharos	UniProt	Action	Type	Activity value (-log[M])	Bioact source	MoA source
Sodium-dependent serotonin transporter	Transporter	P31645	SC6A4_HUMAN	INHIBITOR	Ki	7.95	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Sodium-dependent noradrenaline transporter	Transporter	P23975	SC6A2_HUMAN	INHIBITOR	Ki	7.04	SCIENTIFIC LITERATURE	SCIENTIFIC LITERATURE
Sodium-dependent dopamine transporter	Transporter	Q01959	SC6A3_HUMAN		IC50	5.49	CHEMBL
Sodium-dependent serotonin transporter	Transporter		SC6A4_RAT		Ki	8.07	CHEMBL
Glutamate NMDA receptor	Ion channel		NMDZ1_RAT NMDE1_RAT NMDE2_RAT NMDE3_RAT NMDE4_RAT NMD3B_RAT NMD3A_RAT		IC50	5.20	CHEMBL

Showing 1 to 5 of 5 entries

Previous1Next

External reference:

Show entries

Search:

ID	Source
015223	NDDF
015224	NDDF
1433211	RXNORM
175131-60-9	SECONDARY_CAS_RN
204684	MMSL
29577	MMSL
31358	MMSL
4032886	VUID
4032886	VANDF
6917779	PUBCHEM_CID

Showing 1 to 10 of 22 entries

Previous1 2 3Next

Pharmaceutical products:

Show entries

Search:

Product	Category	Ingredients	NDC	Form	Quantity	Route	Marketing	Label
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2212	CAPSULE, EXTENDED RELEASE	120 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2212	CAPSULE, EXTENDED RELEASE	120 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2212	CAPSULE, EXTENDED RELEASE	120 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2220	CAPSULE, EXTENDED RELEASE	20 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2220	CAPSULE, EXTENDED RELEASE	20 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2220	CAPSULE, EXTENDED RELEASE	20 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2240	CAPSULE, EXTENDED RELEASE	40 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2240	CAPSULE, EXTENDED RELEASE	40 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2240	CAPSULE, EXTENDED RELEASE	40 mg	ORAL	NDA	35 sections
Fetzima	HUMAN PRESCRIPTION DRUG LABEL	1	0456-2280	CAPSULE, EXTENDED RELEASE	80 mg	ORAL	NDA	35 sections

Showing 1 to 10 of 24 entries

Previous1 2 3Next